Relation of serum vascular endothelial growth factor as an ... - MedIND
Recommend Documents
Division of Gynecologic Oncology, Departments of Obstetrics and ... cancer, 16 with low malignant potential (LMP) ovarian tumors, and 34 women ... regarding the utility of serum VEGF levels in predicting clinical .... ovarian and other cancers.
ovarian cancer compared with those with benign disease or. LMP tumors. Among .... tive VEGF levels, 1 had Meigs' Syndrome (871 pg/ml) and another had an ...
Latar belakang: Respons inflamasi pada fase akut strok iskemik akan memicu ... Metode: Penelitian ini menggunakan desain kohort longitudinal terhadap 64 ...
ovarian cancer compared with those with benign disease or. LMP tumors. Among .... tive VEGF levels, 1 had Meigs' Syndrome (871 pg/ml) and another had an ...
Jul 20, 2001 - Jauniaux, E., Watson, A. and Burton, G. (2001) Evaluation of respiratory gases and ... Lee, A., Christenson, L.K., Stouffer, R.L. et al. (1997) ...
Feb 28, 2019 - In lymphangioleiomyomatosis (LAM), tuberous sclerosis gene mutations ... We determined serum VEGF-D levels from 108 LAM patients, ...
As complex tissues become developed for applications in clinical trials .... six-well plate was consolidated into one sample, defined as a biolog- ical replicate in ..... phorylation for the majority of the time course when PF-4 was present, which ..
Oct 7, 1994 - (angiogenesis/hypoxia/Muller cells/retinopathy of prematurity). ERIC A. PIERCE*, ROBERT L. AVERYt, ELIOT D. FOLEY*, LLOYD P. AIELLOt, ...
by the BIH Pathology Foundation, Inc., and under terms of a con- tract from .... VPFNEGF, Microvascular Hyperpermeability, and Angiogenesis 1031. AJP May ...
and non-smoking OSCC patients with different VEGF-SNPs between 2006 and ..... polymerase chain reaction; RFLP, restriction fragment length polymorphism.
of Texas. Health. Sciences. Center at San Antonio. San. Antonio,. TX. Correspondence ..... of the Medical. School of Marburg. University. Immunofluorescence and ... immunofluorescence and double-label immunohistochemistry tech- niques. .... San Diego
M. Cruce. 3. 1SPITALUL CLINIC DE URGENTA âSFANTUL PANTELIMONâ BUCURESTI. 2SPITALUL MAI DE ..... Kim M.I., Kim S.Y., Lee J.J. Prognostic effect of ...
stage III and IV disease and inversely correlated with serum ... and 8 with stage IV disease. ..... Menetrier-Caux C, Montmain G, Dieu MC, et al: Inhibition of.
Background: The role of vascular endothelial growth fac- tor (VEGF) in the pathogenesis of retinopathy of prematurity. (ROP) has been clearly established.
Jul 7, 2013 - squamous cell carcinoma,â Virchows Archiv, vol. 436, no. 3, pp. 243â248, 2000. [8] Z.-J. Shang, J.-R. Li, and Z.-B. Li, âUpregulation of serum.
Jul 7, 2013 - Mean VEGF levels in sera of patients with salivary gland tumors (574.9 ± .... matrix metalloproteinase-3 in patients with oral Lichen planus,â.
Aug 15, 2009 - Apgar BS, Brotzman G. Management of cervical cytologic abnormalities. Am Fam Physician. 2004;70:1905-1916. 3. Branca M, Giorgi C, Santini ...
neoplastic tissues is vascular endothelial growth factor (VEGF). Aim: We ..... may be a target of a novel treatment with anti-VEGF antibodies or VEGF receptor ...
Significance of serum vascular endothelial growth factor and cancer antigen 15.3 in patients with triple negative breast cancer. Priyanka Chanana1, Awadesh ...
constitute a significant proportion of orphan pulâ monary disorders. PLDs include such rare diseasâ es as lymphangioleiomyomatosis (LAM), pulmoâ.
Objectives. Necrotizing vasculitis and granuloma formation are the predominant features of Wegener's .... piratory failure, cerebral vasculitis, or acute abdominal.
Apr 5, 2005 - demonstrating that breast cancer metastases express VEGF strongly and ..... factor also stimulates production of tissue factor (a procoagulant).
VEGF in quail resulted in hypervascularity and hyper- the disease. A majority of WG patients have classic antineutrophil cytoplasmic antibodies (c-ANCA) [2],.
Relation of serum vascular endothelial growth factor as an ... - MedIND
Jul 10, 2006 - Serum NO level was determined as the concentration of nitrite plus nitrate ( NO2+ NO3). Nitrate was reduced to nitrite by nitrate reductase and ...
Indian J Med Res 125, June 2007, pp 747-751
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients Dildar Konukoglu, Mehtap Sultan Turhan, Varol Celik+ & Hande Turna*
Departments of Biochemistry, University, Istanbul, Turkey
+
Surgery & *Medical Oncology, Cerrahpasa Medical Faculty, Istanbul
Received July 10, 2006
Background & objectives: The primary mediator of angiogenesis is vascular endothelial growth factor (VEGF). It is well documented that angiogenic activity in human cancer depends on nitric oxide (NO) levels in tissues. Additionally, urokinase type plasminogen activator (u-PA) plays a role in cell adhesion and migration. Serum VEGF and its relationship between NO and u-PA concentrations are poorly reported in breast cancer patients. The aim of this study was to investigate the relationship between serum levels of VEGF and NO and u-PA in patients with breast cancer. Methods: Serum concentrations of VEGF, NO and u-PA were measured in groups of pre-operative breast cancer patients without metastasis (n=20), post-operative breast cancer patients without metastasis (four wk after the operation, n=20), breast cancer patients with metastasis (n=23), patients with benign breast disease (n=11) and healthy female controls (n=20). Results: There was no difference in serum concentrations of VEGF, NO and u-PA between controls and patients with benign breast disease. Serum VEGF, NO and u-PA concentrations were significantly higher in pre-operative breast cancer patients than in controls and in patients with benign breast diseases (P
